Another Japanese company is building its Chinese presence through a local partnership, this time eye care specialist Santen, which is planning to link with a state-owned company in Chongqing.
The strategic attractions of China's growing health care market are proving enticing to another Japanese pharma company, which has unveiled plans for a production-focused joint venture.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs
Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.
Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.
